HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- New oncology care models crucial as more patients live longer
-
- Antiplatelet treatment reduced mortality among patients with diabetes
- Bosutinib failed to improve response rate in newly diagnosed CML
- Denosumab decreases abnormal giant cells in patients with giant-cell tumor of the bone
- Drugmakers launch TransCelerate BioPharma to speed testing
- FDA: Manufacturer recalls Reumofan Plus
- HIV/HCV coinfected patients at increased risk for cancer
- Investigators take part in training
- Mobile compression device superior to warfarin in preventing major bleeding events after THA, TKA
-
- Professor receives cancer care prize
- Professors receive grant from NCI
- Program designed to increase survival
- Researcher wins memorial award
- US Census: Fewer Americans uninsured in 2011
- Ziv-aflibercept failed to improve outcomes in NSCLC
- AMA, medical societies urge Congress to stall 2% cut in Medicare payments
- FDA approves Stivarga to treat metastatic colorectal cancer
-
- A 66-year-old female diagnosed with atypical carcinoid tumor Munir Ghesani, MD, FACNM; Michael Thomas Starc, MD; Abdelaziz Elhaddad, MD
- Abiraterone acetate significantly improved survival in patients with advanced prostate cancer
- Analysis identifies genetic mutations linked to SCLC tumor growth
- Best-practice protocol reduced CLABSI rates in pediatric cancer patients
- BMI declined significantly among children who underwent alloHSCT
- Dacomitinib improved PFS, toxicity in advanced NSCLC
- Groups develop appropriate use criteria for Mohs' surgery
- Higher detection rates, disease free-survival associated with SPECT/CT
-
- HPV DNA alone poor biomarker for HPV-driven oropharyngeal cancers
- KIR gene activation linked to allogeneic hematopoietic stem cell transplantation outcomes in AML
- Novel drug may be effective against resistant multiple myeloma
- Novel molecule provides insight into targets for B-cell malignancies
- Obesity increased risk for prostate cancer progression
- Outcomes similar between minimally invasive esophagectomy, open techniques in esophageal cancer
- Poor neurocognitive outcomes observed in survivors of childhood Hodgkin’s lymphoma
- Presence of CKD ups risk for stroke, systemic thromboembolism in AF patients
-
- Prolonged analgesic use failed to reduce postmenopausal breast cancer risk
- Radiation improved survival in children with nonmetastatic medulloblastoma
- Random cell mutations in AML genomes unrelated to leukemia
- Social factors associated with very thick melanomas
- Axillary lymph node removal may benefit women at high risk for residual nodal disease
- Blood leukocyte changes matched those in breast tumor stroma
- Cabozantinib prolonged PFS in patients with MTC
- Chemotherapy did not increase risk for AML, MDS in early breast cancer
-
- Crizotinib superior to single-agent chemotherapy for ALK-positive advanced NSCLC
- Demographic factors associated with decision to undergo CPM
- Disparities identified among women who undergo immediate breast reconstruction
- Evidence supports optional use of RAI for papillary thyroid cancer
- Gefitinib extended PFS in esophageal cancer
- Longer trastuzumab treatment failed to improve outcomes in HER-2–positive breast cancer
- Patient survey: Sexual dysfunction neglected in routine care
- Program designed to meet survivors’ medical, psychosocial needs
-
- Racial, ethnic disparities identified in breast cancer care
- Sorafenib as salvage regimen failed to extend OS in NSCLC
- Targeted drugs for mRCC effective in first-line treatment
- Vaccine benefited patients with low expression of HER-2 tumors